Cargando…

Phase II study of nedaplatin and irinotecan with concurrent thoracic radiotherapy in patients with locally advanced non-small-cell lung cancer

BACKGROUND: Current international guidelines recommend the use of platinum-based chemotherapy with thoracic radiotherapy (TRT) for patients with locally advanced non-small-cell lung cancer (NSCLC). METHODS: Patients with unresectable stage IIIA or IIIB NSCLC were treated with nedaplatin (NP) at 50 m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oshita, F, Ohe, M, Honda, T, Murakami, S, Kondo, T, Saito, H, Noda, K, Yamashita, K, Nakayama, Y, Yamada, K
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2010
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990596/ https://www.ncbi.nlm.nih.gov/pubmed/20940720 http://dx.doi.org/10.1038/sj.bjc.6605875

Ejemplares similares

Radiotherapy Combined With Concurrent Nedaplatin-Based Chemotherapy for Stage II–III Esophageal Squamous Cell Carcinoma
por: Zhu, Huiping, et al.
Publicado: (2022)

Clinical efficacy of neoadjuvant chemotherapy with irinotecan (CPT-11) and nedaplatin followed by radical hysterectomy for locally advanced cervical cancer
por: Abou-Taleb, Hisham A, et al.
Publicado: (2016)

A phase II study of concurrent chemo-radiotherapy with weekly nedaplatin in advanced squamous cell carcinoma of the uterine cervix
por: Yuan, Guangwen, et al.
Publicado: (2014)

Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer
por: Yamada, M, et al.
Publicado: (2002)

Induction cisplatin–irinotecan followed by concurrent cisplatin–irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial
por: Michel, P, et al.
Publicado: (2006)

Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer [seecomments]
por: Yokoyama, A., et al.
Publicado: (1998)

Concurrent chemoradiotherapy with raltitrexed and nedaplatin regimen for esophageal squamous cell carcinoma
por: Qiu, Xiangnan, et al.
Publicado: (2020)

Concurrent chemoradiotherapy using gemcitabine and nedaplatin in recurrent or locally advanced head and neck squamous cell carcinoma
por: Huo, Rui-Xue, et al.
Publicado: (2022)

A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer
por: Willeke, F, et al.
Publicado: (2007)

A phase I study of nedaplatin, pemetrexed and thoracic intensity-modulated radiotherapy for inoperable stage III lung adenocarcinoma
por: Lu, Yiyu, et al.
Publicado: (2016)

Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer
por: Takeda, K, et al.
Publicado: (1999)

Evaluation of the efficacy and feasibility of concurrent weekly docetaxel-nedaplatin and hypo-fractionated radiotherapy in atypical histologic subtypes of primary and metastatic mediastinal malignancies
por: Meng, FanJun, et al.
Publicado: (2022)

Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer
por: Inokuchi, M, et al.
Publicado: (2006)

Propensity score matching analysis to comparing cisplatin versus nedaplatin based doublet agent concurrent chemoradiotherapy for locally advanced cervical cancer
por: Zhang, Yue, et al.
Publicado: (2023)

Phase I–II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer
por: Tsuda, H, et al.
Publicado: (2004)

Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer
por: Klautke, G, et al.
Publicado: (2005)

Hematological Toxicities of Concurrent Chemoradiotherapies in Head and Neck Cancers: Comparison Among Cisplatin, Nedaplatin, Lobaplatin, and Nimotuzumab
por: Wu, Qiuji, et al.
Publicado: (2021)

Efficacy and feasibility of ambulatory treatment-based monthly nedaplatin plus S-1 in definitive or salvage concurrent chemoradiotherapy for early, advanced, and relapsed esophageal cancer
por: Yamashita, Hideomi, et al.
Publicado: (2016)

Efficacy and Side Effects of Irinotecan Combined with Nedaplatin versus Paclitaxel Combined with Cisplatin in Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer and Tumor Marker Analysis: Based on a Retrospective Analysis
por: Jiang, Yu, et al.
Publicado: (2022)

Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer
por: Ohyanagi, F, et al.
Publicado: (2009)

Efficacy and toxicity of three concurrent chemoradiotherapy regimens in treating nasopharyngeal carcinoma: Comparison among cisplatin, nedaplatin, and lobaplatin
por: Liang, Xuexia, et al.
Publicado: (2022)

A phase III randomized, controlled trial of nedaplatin versus cisplatin concurrent chemoradiotherapy in patients with cervical cancer
por: Yang, X., et al.
Publicado: (2022)

Combination Chemotherapy with Nedaplatin and Cyclophosphamide in Human Ovarian Cancer Model
por: Uchida, Naomi, et al.
Publicado: (1999)

Retracted: Efficacy and Side Effects of Irinotecan Combined with Nedaplatin versus Paclitaxel Combined with Cisplatin in Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer and Tumor Marker Analysis: Based on a Retrospective Analysis
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma
por: Sekine, I, et al.
Publicado: (2004)

Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer
por: Cleary, James M., et al.
Publicado: (2016)

Nedaplatin: a cisplatin derivative in cancer chemotherapy
por: Shimada, Muneaki, et al.
Publicado: (2013)

Phase II trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinoma
por: Peng, Pei-Jian, et al.
Publicado: (2015)

Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study
por: Klautke, G, et al.
Publicado: (2006)

Toxic epidermal necrolysis in a patient receiving concurrent phenytoin and whole brain and thoracic radiotherapy
por: Ahmed, Imtiaz, et al.
Publicado: (2014)

Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507
por: Sekine, I, et al.
Publicado: (2003)

Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Patients With Stage IIB-IVA Cervical Cancer: A Randomized Phase III Trial
por: He, Shasha, et al.
Publicado: (2022)

Long-term bresults of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study
por: Jingu, Keiichi, et al.
Publicado: (2012)

Nedaplatin-based chemotherapy or cisplatin-based chemotherapy combined with intensity-modulated radiotherapy achieve similar efficacy for stage II-IVa nasopharyngeal carcinoma patients
por: Deng, Chao, et al.
Publicado: (2022)

Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II study
por: Ohnuma, Hiroyuki, et al.
Publicado: (2018)

Randomized phase II trial of S‐1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non‐small cell lung cancer
por: Shimokawa, Tsuneo, et al.
Publicado: (2020)

Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer
por: Goto, K, et al.
Publicado: (2004)

Comparative Nephrotoxicity of Cisplatin and Nedaplatin: Mechanisms and Histopathological Characteristics
por: Uehara, Takeki, et al.
Publicado: (2011)

Nedaplatin: A Radiosensitizing Agent for Patients with Cervical Cancer
por: Mabuchi, Seiji, et al.
Publicado: (2011)

Feasibility, tolerability, and efficacy of the concurrent addition of erlotinib to thoracic radiotherapy in locally advanced unresectable non-small-cell lung cancer: a Phase II trial
por: Martínez, Enrique, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ebv17ov9260laoaqahbiuj706a